| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
From the Lundberg Laboratory for Cancer Research,*
Department of Pathology, Göteborg University, Göteborg,Sweden; and the Center for Human Genetics and GeneticCounseling,
University of Bremen,Bremen, Germany
Carcinoma ex pleomorphic adenoma (CexPA) is a carcinoma developing within a pre-existing benign pleomorphic adenoma (PA). Here we describe the identification and characterization of a series of genetic events leading to translocation, deletion/amplification, and overexpression of the HMGIC and MDM2 genes in a CexPA at an early stage of development. The tumor had a pseudodiploid stemline karyotype with a del(5)(q22–23q32–33) and a t(10;12)(p15;q14–15). In addition, there were several sidelines with double minute chromosomes (dmin) or homogeneously staining regions (hsr). Fluorescence in situ hybridization (FISH) mapping revealed that the 12q14–15 breakpoint was located centromeric to HMGIC and that the entire gene was juxtaposed to the der(10) chromosome. Detailed analysis of cells with dmin and hsr revealed that HMGIC and MDM2 were deleted from the der(10) and that the dmin and hsr were strongly positive for both genes. Southern blot analysis confirmed that both HMGIC and MDM2 were amplified and that no gross rearrangements of the genes had occurred. Immunostaining revealed that the HMGIC protein was highly overexpressed particularly in the large polymorphic cells within the carcinomatous part of the tumor. These findings suggest that amplification and overexpression of HMGIC and possibly MDM2 might be important genetic events that may contribute to malignant transformation of benign PA.
This article has been cited by other articles:
 |
|
 |
|
  S. Di Palma, M. B K Lambros, K. Savage, C. Jones, A. Mackay, T. Dexter, M. Iravani, K. Fenwick, A. Ashworth, and J. S Reis-Filho Oncocytic change in pleomorphic adenoma: molecular evidence in support of an origin in neoplastic cells J. Clin. Pathol., May 1, 2007; 60(5): 492 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Storlazzi, T. Fioretos, C. Surace, A. Lonoce, A. Mastrorilli, B. Strombeck, P. D'Addabbo, F. Iacovelli, C. Minervini, A. Aventin, et al. MYC-containing double minutes in hematologic malignancies: evidence in favor of the episome model and exclusion of MYC as the target gene Hum. Mol. Genet., March 15, 2006; 15(6): 933 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Declercq, F. Van Dyck, C. V. Braem, I. C. Van Valckenborgh, M. Voz, M. Wassef, L. Schoonjans, B. Van Damme, L. Fiette, and W. J.M. Van de Ven Salivary Gland Tumors in Transgenic Mice with Targeted PLAG1 Proto-Oncogene Overexpression Cancer Res., June 1, 2005; 65(11): 4544 - 4553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-i. Maruya, H.-W. Kim, R. S. Weber, J. J. Lee, M. Kies, M. A. Luna, J. G. Batsakis, and A. K. El-Naggar Gene Expression Screening of Salivary Gland Neoplasms: Molecular Markers of Potential Histogenetic and Clinical Significance J. Mol. Diagn., August 1, 2004; 6(3): 180 - 190. [Abstract] [Full Text]
|
|
|
|
|
|
C. T. Storlazzi, T. Fioretos, K. Paulsson, B. Strombeck, C. Lassen, T. Ahlgren, G. Juliusson, F. Mitelman, M. Rocchi, and B. Johansson Identification of a commonly amplified 4.3 Mb region with overexpression of C8FW, but not MYC in MYC-containing double minutes in myeloid malignancies Hum. Mol. Genet., July 15, 2004; 13(14): 1479 - 1485. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
